Efficacy and safety of fruquintinib as third- or further-line therapy for patients with advanced bone and soft tissue sarcoma: a multicenter retrospective study

Fruquintinib is an oral small-molecule angiogenesis inhibitor, markedly specifically inhibited vascular endothelial growth factor 2 (VEGFR2). This retrospective study aimed to evaluate the safety and efficacy of fruquintinib, or in combination with immunotherapy or chemotherapy in patients with bone...

Descripción completa

Detalles Bibliográficos
Autores principales: Ding, Xiaomin, Liu, Yuan, Zhang, YaWen, Liang, Jinrong, Li, Qian, Hu, Haiyan, Zhou, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Clinical Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10344427/
https://www.ncbi.nlm.nih.gov/pubmed/36539356
http://dx.doi.org/10.1097/CAD.0000000000001482

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10344427/
https://www.ncbi.nlm.nih.gov/pubmed/36539356
http://dx.doi.org/10.1097/CAD.0000000000001482

Ejemplares similares